CDER published guidance on quality attribute considerations for chewable tablets providing manufacturers with metrics on how these drug products should be assessed during their development. The guidance also provides recommendations for sponsors and applicants regarding the submission of developmental, manufacturing, and labeling information and certain CMC supplements to those applications.
[membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
